Notice of Results

 

TIDMLMT 
 
RNS Number : 8657O 
Lombard Medical Technologies PLC 
16 March 2009 
 

Press Information 
 
 
Lombard Medical Technologies PLC 
 
 
Notification of Results 
 
 
London, UK, 16 March 2009 - Lombard Medical Technologies PLC (AIM: LMT), the 
specialist medical device company, will be announcing its preliminary results 
for the year ended 31 December 2008 on Wednesday, 1 April 2009. 
 
 
An analyst briefing will be held at 09.30am on 1 April 2009 at the offices of 
Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2. 
 
 
 
 
Enquiries: 
+--------------------------------------------------+----------------------+ 
| Lombard Medical Technologies PLC                 |    Tel: [phone] | 
| Simon Neathercoat, Non-executive Chairman        |              750 800 | 
| Brian Howlett, Chief Executive Officer           |                      | 
| Tim Hall, Finance Director                       |                      | 
+--------------------------------------------------+----------------------+ 
|                                                  |                      | 
+--------------------------------------------------+----------------------+ 
| Financial Dynamics                               | Tel: [phone] | 
| Jonathan Birt / Susan Quigley                    |                 3113 | 
+--------------------------------------------------+----------------------+ 
|                                                  |                      | 
+--------------------------------------------------+----------------------+ 
| Nomura Code Securities Limited                   | Tel: [phone] | 
| Juliet Thompson / Richard Potts                  |                 1200 | 
+--------------------------------------------------+----------------------+ 
 
 
 
 
Notes to editors 
About Lombard Medical 
Lombard Medical Technologies PLC is a medical devices group developing stent 
grafts and other medical products for use in the treatment of vascular disease. 
The Company's lead product, Aorfix(TM), is an endovascular stent graft for the 
treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of 
the aorta which, if untreated, may rupture and cause death. Approximately 1.7 
million people have AAAs in the US where it is the 13th largest cause of death. 
The market for endovascular stent grafts for the treatment of AAA is currently 
worth over $600 million and is expected to grow to around a $1 billion by 2010. 
Aorfix(TM) is currently being commercialised in the EU, with a pivotal clinical 
trial ongoing in the USA. 
The Company's Polymer Coatings Division has developed a novel hydrophilic 
surface treatment to reduce friction on catheters called GlideMax(TM), which is 
available for licensing, and is using its polymer coating technology in a number 
of research collaborations developing novel products for the $5 billion 
drug-eluting stent market. 
The Company is headquartered in Oxfordshire, with operations in Yorkshire, 
Ayrshire and Boston, USA. 
Further background on the Company can be found at www.lombardmedical.com. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NORKGGMFVFVGLZM